Compare Incyte Corporation (INCY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs T Rowe Price Group Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while T Rowe Price Group Inc trades at $113.73 (market cap $24.26B). The key difference: Incyte Corporation and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TROW | |
|---|---|---|
Market Cap | $24.54B | $24.26B |
Sector | Health | Financials |
52-Week High | $129.93 | $121.68 |
52-Week Low | $81.61 | $86.19 |
Enterprise Value | $20.04B | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
T. Rowe Price (TROW) trades at $111.49, down 2.0% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 11.42, net income margin of 29.26%, and consistent dividend payments of $1.30 per share. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51 estimated, driven by higher assets under management and advisory revenue.
The outlook is mixed: strong profitability and a consensus price target of $112.17 offer upside, but bearish technicals and expense pressures pose risks. Investor sentiment is cautious with 63% analyst hold ratings, reflecting concerns over net outflows and market volatility impacting asset management fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
